Literature DB >> 11355440

Oral manifestation of sporotrichosis in AIDS patients.

F M Aarestrup1, R O Guerra, B J Vieira, R M Cunha.   

Abstract

A wide spectrum of oral lesions has been associated with human immunodeficiency viral infection (HIV), or AIDS. This report describes the case of an HIV-infected patient who developed a case of disseminated sporotrichosis whose first clinical sign was the presence of orofacial lesions. A histopathological study of this patient's biopsy specimens taken from the oropharyngeal lesions revealed a number of rounded and/or oval free-spore forms of Sporothrix schenkii, the identification of which was corroborated by culturing skin lesion exudate on Sabouraud's glucose agar. To the best of our knowledge to date, this is the first time a case of the oral manifestation of sporotrichosis in association with HIV infection has been described in the dental literature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355440

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  3 in total

Review 1.  The impact of sporotrichosis in HIV-infected patients: a systematic review.

Authors:  José A S Moreira; Dayvison F S Freitas; Cristiane C Lamas
Journal:  Infection       Date:  2015-02-21       Impact factor: 3.553

2.  Detrimental role of endogenous nitric oxide in host defence against Sporothrix schenckii.

Authors:  Karla Simone S Fernandes; Edward Helal Neto; Marcelly M S Brito; João S Silva; Fernando Q Cunha; Christina Barja-Fidalgo
Journal:  Immunology       Date:  2008-01-09       Impact factor: 7.397

3.  Response of Cytokines and Hydrogen Peroxide to Sporothrix schenckii Exoantigen in Systemic Experimental Infection.

Authors:  Danielle Cardoso Geraldo Maia; Amanda Costa Gonçalves; Lucas Souza Ferreira; Francine Alessandra Manente; Deivys Leandro Portuondo; José Carlos Rebuglio Vellosa; Marisa Campos Polesi; Alexander Batista-Duharte; Iracilda Zeppone Carlos
Journal:  Mycopathologia       Date:  2015-11-24       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.